{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:31:12Z","timestamp":1794540672745,"version":"4.9.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chimeric antigen receptor-engineered T (CAR-T) cells have shown promising efficacy in patients with relapsed\/refractory B cell acute lymphoblastic leukemia (R\/R B-ALL). However, challenges remain including long manufacturing processes that need to be overcome. We presented the CD19-targeting CAR-T cell product GC007F manufactured next-day (FasTCAR-T cells) and administered to patients with R\/R B-ALL. A total of 21 patients over 14 years of age with CD19<jats:sup>+<\/jats:sup>\u2009\u2009R\/R B-ALL were screened, enrolled and infused with a single infusion of GC007F CAR-T at three different dose levels. The primary objective of the study was to assess safety, secondary objectives included pharmacokinetics of GC007F cells in patients with R\/R B-ALL and preliminary efficacy. We were able to demonstrate in preclinical studies that GC007F cells exhibited better proliferation and tumor killing than conventional CAR-T (C-CAR-T) cells. In this investigator-initiated study all 18 efficacy-evaluable patients achieved a complete remission (CR) (18\/18, 100.00%) by day 28, with 17 of the patients (94.4%) achieving CR with minimal residual disease (MRD) negative. Fifteen (83.3%) remained disease free at the 3-month assessment, 14 patients (77.8%) maintaining MRD negative at month 3. Among all 21 enrolled patients, the median peak of CAR-T cell was on day 10, with a median peak copy number of 104899.5\/\u00b5g DNA and a median persistence period of 56 days (range: 7\u2013327 days). The incidence of cytokine release syndrome (CRS) was 95.2% (<jats:italic>n<\/jats:italic>\u2009=\u200920), with severe CRS occurring in 52.4% (<jats:italic>n<\/jats:italic>\u2009=\u200911) of the patients. Six patients (28.6%) developed neurotoxicity of any grade. GC007F demonstrated superior expansion capacity and a less exhausted phenotype as compared to (C-CAR-T) cells. Moreover, this first-in-human clinical study showed that the novel, next-day manufacturing FasTCAR-T cells was feasible with a manageable toxicity profile in patients with R\/R B-ALL.<\/jats:p>","DOI":"10.1038\/s41408-022-00688-4","type":"journal-article","created":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T17:22:52Z","timestamp":1656091372000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"12","author":[{"given":"Cheng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8808-7072","authenticated-orcid":false,"given":"Jiaping","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jishi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanbin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ligen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Sersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianjun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei William","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8548-2832","authenticated-orcid":false,"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,24]]},"reference":[{"key":"688_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41409-018-0203-8","volume":"54","author":"C Craddock","year":"2019","unstructured":"Craddock C, Hoelzer D, Komanduri KV. Current status and future clinical directions in the prevention and treatment of relapse following hematopoietic transplantation for acute myeloid and lymphoblastic leukemia. Bone Marrow Transpl. 2019;54:6\u201316.","journal-title":"Bone Marrow Transpl"},{"key":"688_CR2","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2217\/imt-2017-0072","volume":"9","author":"J Liu","year":"2017","unstructured":"Liu J, Zhang X, Zhong JF, Zhang C. CAR-T cells and allogeneic hematopoietic stem cell transplantation for relapsed\/refractory B-cell acute lymphoblastic leukemia. Immunotherapy. 2017;9:1115\u201325.","journal-title":"Immunotherapy"},{"key":"688_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2217\/imt-2018-0089","volume":"11","author":"J Liu","year":"2019","unstructured":"Liu J, Zhang X, Zhong JF, Zhang C. Use of chimeric antigen receptor T cells in allogeneic hematopoietic stem cell transplantation. Immunotherapy. 2019;11:37\u201344.","journal-title":"Immunotherapy"},{"key":"688_CR4","doi-asserted-by":"publisher","first-page":"e16498","DOI":"10.1097\/MD.0000000000016498","volume":"98","author":"C Zhang","year":"2019","unstructured":"Zhang C, Ma Y-Y, Liu J, Liu Y, Gao L, Gao L, et al. Preventive infusion of donor-derived CAR-T cells after haploidentical transplantation: Two cases report. Med. 2019;98:e16498.","journal-title":"Med"},{"key":"688_CR5","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/CJI.0000000000000233","volume":"41","author":"C Zhang","year":"2018","unstructured":"Zhang C, Kong P-Y, Li S, Chen T, Ni X, Li Y, et al. Donor-derived CAR-T cells serve as a reduced-intensity conditioning regimen for haploidentical stem cell transplantation in treatment of relapsed\/refractory acute lymphoblastic leukemia: case report and review of the literature. J Immunother. 2018;41:306\u201311.","journal-title":"J Immunother"},{"key":"688_CR6","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1038\/s41375-020-01056-6","volume":"35","author":"C Zhang","year":"2021","unstructured":"Zhang C, Wang X-Q, Zhang R-L, Liu F, Wang Y, Yan Z-L, et al. Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant. Leukemia. 2021;35:1563\u201370.","journal-title":"Leukemia"},{"key":"688_CR7","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1016\/j.ymthe.2020.09.015","volume":"28","author":"J Wagner","year":"2020","unstructured":"Wagner J, Wickman E, DeRenzo C, Gottschalk S. CAR T cell therapy for solid tumors: bright future or dark reality? Mol Ther. 2020;28:2320\u201339.","journal-title":"Mol Ther"},{"key":"688_CR8","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1021\/acsptsci.1c00188","volume":"4","author":"B Maru","year":"2021","unstructured":"Maru B, Nadeau L, McKeague M. Enhancing CAR-T cell therapy with functional nucleic acids. ACS Pharm Transl Sci. 2021;4:1716\u201327.","journal-title":"ACS Pharm Transl Sci"},{"key":"688_CR9","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Rivi\u00e8re I, Gonen M, Wang X, S\u00e9n\u00e9chal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl J Med. 2018;378:449\u201359.","journal-title":"N. Engl J Med"},{"key":"688_CR10","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl J Med. 2018;378:439\u201348.","journal-title":"N. Engl J Med"},{"key":"688_CR11","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-020-00910-5","volume":"13","author":"R Huang","year":"2020","unstructured":"Huang R, Li X, He Y, Zhu W, Gao L, Liu Y, et al. Recent advances in CAR-T cell engineering. J Hematol Oncol. 2020;13:86.","journal-title":"J Hematol Oncol"},{"key":"688_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","volume":"34","author":"JN Brudno","year":"2019","unstructured":"Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Blood Rev. 2019;34:45\u201355.","journal-title":"Blood Rev"},{"key":"688_CR13","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2326-6066.CIR-17-0405","volume":"6","author":"S Ghassemi","year":"2018","unstructured":"Ghassemi S, Nunez-Cruz S, O\u2019Connor RS, Fraietta JA, Patel PR, Scholler J, et al. Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells. Cancer Immunol Res. 2018;6:1100\u20139.","journal-title":"Cancer Immunol Res"},{"key":"688_CR14","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1080\/17474086.2020.1753501","volume":"13","author":"M Namuduri","year":"2020","unstructured":"Namuduri M, Brentjens RJ. Enhancing CAR T cell efficacy: the next step toward a clinical revolution? Expert Rev Hematol. 2020;13:533\u201343.","journal-title":"Expert Rev Hematol"},{"key":"688_CR15","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.copbio.2018.01.025","volume":"53","author":"P Vormittag","year":"2018","unstructured":"Vormittag P, Gunn R, Ghorashian S, Veraitch FS. A guide to manufacturing CAR T cell therapies. Curr Opin Biotechnol. 2018;53:164\u201381.","journal-title":"Curr Opin Biotechnol"},{"key":"688_CR16","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transpl"},{"key":"688_CR17","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nrc3322","volume":"12","author":"L Gattinoni","year":"2012","unstructured":"Gattinoni L, Klebanoff CA, Restifo NP. Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer. 2012;12:671\u201384.","journal-title":"Nat Rev Cancer"},{"key":"688_CR18","doi-asserted-by":"publisher","first-page":"E36","DOI":"10.3390\/cancers8030036","volume":"8","author":"V Golubovskaya","year":"2016","unstructured":"Golubovskaya V, Wu L. Different subsets of T cells, memory, effector functions, and CAR-T immunotherapy. Cancers . 2016;8:E36.","journal-title":"Cancers"},{"key":"688_CR19","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","volume":"129","author":"RA Gardner","year":"2017","unstructured":"Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129:3322\u201331.","journal-title":"Blood"},{"key":"688_CR20","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385:517\u201328.","journal-title":"Lancet"},{"key":"688_CR21","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1172\/JCI81217","volume":"126","author":"CA Klebanoff","year":"2016","unstructured":"Klebanoff CA, Scott CD, Leonardi AJ, Yamamoto TN, Cruz AC, Ouyang C, et al. Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy. J Clin Invest. 2016;126:318\u201334.","journal-title":"J Clin Invest"},{"key":"688_CR22","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1182\/blood-2014-05-578583","volume":"124","author":"AB van der Waart","year":"2014","unstructured":"van der Waart AB, van de Weem NMP, Maas F, Kramer CSM, Kester MGD, Falkenburg JHF, et al. Inhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy. Blood. 2014;124:3490\u20133500.","journal-title":"Blood"},{"key":"688_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1089\/hgtb.2016.120","volume":"27","author":"TL Lu","year":"2016","unstructured":"Lu TL, Pugach O, Somerville R, Rosenberg SA, Kochenderfer JN, Better M, et al. A rapid cell expansion process for production of engineered autologous CAR-T cell therapies. Hum Gene Ther Methods. 2016;27:209\u201318.","journal-title":"Hum Gene Ther Methods"},{"key":"688_CR24","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1172\/JCI32103","volume":"118","author":"C Berger","year":"2008","unstructured":"Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest. 2008;118:294\u2013305.","journal-title":"J Clin Invest"},{"key":"688_CR25","doi-asserted-by":"publisher","first-page":"17469","DOI":"10.1073\/pnas.0907448106","volume":"106","author":"CS Hinrichs","year":"2009","unstructured":"Hinrichs CS, Borman ZA, Cassard L, Gattinoni L, Spolski R, Yu Z, et al. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci. 2009;106:17469\u201374.","journal-title":"Proc Natl Acad Sci."},{"key":"688_CR26","doi-asserted-by":"publisher","first-page":"e1072671","DOI":"10.1080\/2162402X.2015.1072671","volume":"5","author":"X Wang","year":"2016","unstructured":"Wang X, Wong CW, Urak R, Taus E, Aguilar B, Chang W-C, et al. Comparison of na\u00efve and central memory derived CD8+ effector cell engraftment fitness and function following adoptive transfer. Oncoimmunology. 2016;5:e1072671.","journal-title":"Oncoimmunology"},{"key":"688_CR27","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/nm.2446","volume":"17","author":"L Gattinoni","year":"2011","unstructured":"Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, et al. A human memory T cell subset with stem cell-like properties. Nat Med. 2011;17:1290\u20137.","journal-title":"Nat Med"},{"key":"688_CR28","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.immuni.2014.05.018","volume":"41","author":"P Graef","year":"2014","unstructured":"Graef P, Buchholz VR, Stemberger C, Flossdorf M, Henkel L, Schiemann M, et al. Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8(+) central memory T cells. Immunity. 2014;41:116\u201326.","journal-title":"Immunity"},{"key":"688_CR29","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1182\/blood-2010-05-286286","volume":"117","author":"CS Hinrichs","year":"2011","unstructured":"Hinrichs CS, Borman ZA, Gattinoni L, Yu Z, Burns WR, Huang J, et al. Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood. 2011;117:808\u201314.","journal-title":"Blood"},{"key":"688_CR30","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.immuni.2016.10.022","volume":"45","author":"P Durek","year":"2016","unstructured":"Durek P, Nordstr\u00f6m K, Gasparoni G, Salhab A, Kressler C, de Almeida M, et al. Epigenomic Profiling of Human CD4+ T Cells Supports a Linear Differentiation Model and Highlights Molecular Regulators of Memory Development. Immunity. 2016;45:1148\u201361.","journal-title":"Immunity"},{"key":"688_CR31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-017-0405-3","volume":"10","author":"J Liu","year":"2017","unstructured":"Liu J, Zhong JF, Zhang X, Zhang C. Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies. J Hematol Oncol. 2017;10:35.","journal-title":"J Hematol Oncol"},{"key":"688_CR32","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","volume":"125","author":"SL Maude","year":"2015","unstructured":"Maude SL, Teachey DT, Porter DL, Grupp SA. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015;125:4017\u201323.","journal-title":"Blood"},{"key":"688_CR33","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","volume":"35","author":"JN Kochenderfer","year":"2017","unstructured":"Kochenderfer JN, Somerville RPT, Lu T, Shi V, Bot A, Rossi J, et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T-cells are associated with high serum interleukin-15 levels. J Clin Oncol. 2017;35:1803\u201313.","journal-title":"J Clin Oncol"},{"key":"688_CR34","doi-asserted-by":"publisher","first-page":"e89580.","DOI":"10.1172\/jci.insight.89580","volume":"2","author":"Y Kagoya","year":"2017","unstructured":"Kagoya Y, Nakatsugawa M, Ochi T, Cen Y, Guo T, Anczurowski M, et al. Transient stimulation expands superior antitumor T cells for adoptive therapy. JCI Insight. 2017;2:e89580.","journal-title":"JCI Insight"},{"key":"688_CR35","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1182\/blood.2019001463","volume":"134","author":"RA Gardner","year":"2019","unstructured":"Gardner RA, Ceppi F, Rivers J, Annesley C, Summers C, Taraseviciute A, et al. Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy. Blood. 2019;134:2149\u201358.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00688-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00688-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00688-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T20:09:32Z","timestamp":1669234172000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00688-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,24]]},"references-count":35,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["688"],"URL":"https:\/\/doi.org\/10.1038\/s41408-022-00688-4","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,24]]},"assertion":[{"value":"15 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"96"}}